Compare APWC & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | PMVP |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 66.1M |
| IPO Year | 1997 | 2020 |
| Metric | APWC | PMVP |
|---|---|---|
| Price | $1.40 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 464.4K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $1.02 |
| 52 Week High | $2.34 | $1.88 |
| Indicator | APWC | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 58.37 |
| Support Level | $1.30 | $1.04 |
| Resistance Level | $1.48 | $1.36 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 31.79 | 84.62 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the PRC, Hong Kong, and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery, and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and the rest of the World.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.